Topic

New Jersey

A collection of 536 issues

How to Get Zolgensma (onasemnogene abeparvovec-xioi) Covered by Humana in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Zolgensma Covered by Humana in New Jersey Zolgensma (onasemnogene abeparvovec-xioi) requires prior authorization from Humana Medicare Advantage plans in New Jersey as a high-cost specialty gene therapy (HCPCS J3399). Coverage requires genetic confirmation of SMA with SMN1 mutation, age under 2 years, negative AAV9 antibody titers, and
6 min read

If Pombiliti Isn't Approved by Aetna (CVS Health) in New Jersey: Formulary Alternatives & Exception Paths

Answer Box If Aetna (CVS Health) denies Pombiliti (cipaglucosidase alfa-atga) in New Jersey, formulary alternatives include Lumizyme (alglucosidase alfa) and Nexviazyme (avalglucosidase alfa-ngpt) as preferred ERTs for late-onset Pompe disease. Request a formulary exception by documenting inadequate response to standard ERTs with objective measures (6-minute walk test, pulmonary function). After
5 min read

UnitedHealthcare's Coverage Criteria for Firdapse (amifampridine) in New Jersey: What Counts as "Medically Necessary"?

Answer Box: Getting Firdapse Approved by UnitedHealthcare in New Jersey UnitedHealthcare requires prior authorization for Firdapse (amifampridine) through OptumRx with confirmed LEMS diagnosis by a neurologist, diagnostic testing (EMG and VGCC antibodies), and no seizure history. No step therapy is required. If denied, you have 60 days to appeal internally,
6 min read

Get Crysvita (Burosumab) Covered by UnitedHealthcare in New Jersey: Prior Authorization, Appeals & Cost Assistance Guide

Answer Box: Fast Track to Coverage Getting Crysvita (burosumab) covered by UnitedHealthcare in New Jersey requires prior authorization with genetic testing or elevated FGF23 levels, specialist involvement, and documentation of failed conventional therapy (especially for adults). Submit through the UnitedHealthcare provider portal with complete medical records. If denied, you have
6 min read